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Aims Women with aortic stenosis develop a more concentric form of LV hypertrophy than men. However, the molecular
factors underlying sex differences in LV remodelling are incompletely understood. We took an unbiased approach to
identify sex-specific patterns in gene expression and pathway regulation, and confirmed the most prominent findings
in human hearts.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
Echocardiography was performed in 104 patients (53.8% women) with aortic stenosis before aortic valve replace-
ment. LV mass, LV end-diastolic diameter, and relative wall thickness were included in a factor analysis to generate
an index classifying LV remodelling as adaptive or maladaptive. Maladaptive remodelling was present in 64.6% of male
and in 32.7% of female patients (P< 0.01). Genome-wide expression profiling of LV samples was performed in a
representative subgroup of 19 patients (52.6% women) compared with samples from healthy controls (n=18). Tran-
scriptome characterization revealed that fibrosis-related genes/pathways were induced in male overloaded ventricles,
while extracellular matrix-related and inflammatory genes/pathways were repressed in female overloaded ventri-
cles (adjusted P< 0.05). We confirmed gene regulation by quantitative real-time reverse transcription–polymerase
chain reaction and immunoblotting analysis, and we further demonstrate the relevance of our findings by histological
documentation of higher fibrosis in men than in women.
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Conclusion We conclude that in pressure overload distinct molecular processes are regulated between men and women.
Maladaptive LV remodelling occurs more frequently in men and is associated with greater activation of profibrotic
and inflammatory markers. Collectively, sex-specific regulation of these processes may contribute to sex differences
in the progression to heart failure.
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Introduction
The response of the heart to pressure overload (PO) is hypertro-
phy. The initial adaptive hypertrophic response of the myocardium
is characterized by structural and molecular changes, such as wall
thickening, and increases in cardiomyocyte size and contractile
protein content without cellular proliferation.1 In later stages, LV
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. hypertrophy becomes maladaptive. This maladaptive remodelling
process is characterized by LV dilation and impaired function. It is
a major risk factor for the development of congestive heart failure
and a cause for ischaemia, arrhythmia, and sudden death.2,3
In PO, there are significant sex differences in LV remodelling and
the transition to heart failure. Women develop more concentric
hypertrophy with smaller ventricular diameter, greater relative wall
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thickness, and a better systolic function, while men demonstrate
more pronounced chamber dilation.4,5 These sex differences are
partly expected to be the outcome of differences in myocardial
collagen mRNA expression and architecture between males and
females.6–8 However, the molecular mechanisms underlying the
sexually dimorphic response of the heart to PO, which may lead
to heart failure, are incompletely understood. Moreover, inflamma-
tion is expected to contribute to sex differences in LV remodelling.
In a recent study, we reported a significant increase in activation of
inflammatory signalling in female mice lacking oestrogen receptor
𝛽.9 However, little is known about the regulation of the inflamma-
tory response in human LV remodelling.
In the present study, we hypothesized that the PO-dependent
regulation of global cardiac gene expression differs markedly
between men and women, and tested this in a genome-wide
expression analysis. Based on resulting differences in gene regu-
lation, we further hypothesized that the cardiac response to PO
in men is mainly characterized by increases in fibrosis and inflam-
mation, while we expected less pronounced effects in women.
We anticipate that unravelling the sex differences in molecular
processes underlying PO will be useful for the development of
strategies for the prevention of heart failure after surgery, includ-
ing transcatheter aortic valve replacement (TAVR), where women
constitute 50% of the patients,10 and may contribute towards the
design of more appropriate and personalized therapies for men and
women.
Methods
Study population
A cohort of 104 patients (53.8% women) with isolated aortic stenosis
and preserved EF undergoing conventional aortic valve replacement
were included in the present study. Patients with a history of structural
or infectious myocardial disease or other co-morbidities, such as
malignancies or systemic diseases that may affect LV remodelling,
were excluded. The study was approved by the Charite University
Hospital Ethics Committee, complies with the principles outlined in
the Declaration of Helsinki, and written consent was obtained from all
patients.
Echocardiography
The echocardiographic measurements were taken 1 week before aor-
tic valve replacement according to the guidelines of the American Soci-
ety of Echocardiography (ASE) and the European Society of Echocar-
diography (ESC). LV mass and LVEF were calculated using standard
procedures,11,12 i.e. according to the Devereux formula, and relative
wall thickness was calculated using the formula 2× posterior wall thick-
ness/LV diastolic diameter. We estimated mean and maximum aortic
valve pressure gradients by the modified Bernoulli equation, by appli-
cation of the flow velocity time integral over the ejection period in
continuous wave Doppler recordings with a 100mm/s time scale on
the x-axis for all patients.
Hybridization and microarray profiling
Biopsies from the lateral LV wall of 19 aortic stenosis patients (52.6%
women) were collected during aortic valve replacement and frozen ..
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.. immediately in liquid nitrogen until further processing. Samples from
the lateral LV wall of non-diseased human hearts technically unusable
for transplantation obtained from general organ donors were frozen
immediately in liquid nitrogen until further processing and used as con-
trols [n= 18; 44.4% female; mean age= 55.6 years (men) and 55.8 years
(women)] for comparisons with male and female diseased LV biopsies,
respectively, as performed previously.13–15 To avoid potential sources
of error and the introduction of bias and variation into the study due
to technical reasons, we were consistent with tissue sampling, i.e. loca-
tion, collection, processing, and storage, in all groups. Experimental
protocols were approved by the Scientific and Research Ethical Com-
mittee of the Medical Scientific Board at the Hungarian Ministry of
Health (ETT-TUKEB: 4991-0/2010-1018EKU).
Total RNA was isolated using the RNeasy Fibrous Tissue Mini
kit (Qiagen) following the manufacturer’s protocol. RNA quality and
quantity were established using a 2100 Bioanalyzer (Agilent Technolo-
gies) ensuring adequate RNA quality and that all samples, i.e. healthy
and diseased, can be compared. Biotinylated complementary RNA
(cRNA) was prepared and hybridized to the Human Gene 1.0 ST array
(Affymetrix) according to the standard Affymetrix processing proto-
col. The array was scanned in a GeneChip Scanner 3000. The quality of
hybridization was assessed in all samples following the manufacturer’s
recommendations. Microarray data are deposited in the ArrayExpress
database under accession number E-MEXP-3684.
Microarray data analysis
The computational and statistical analysis of the microarray data was
carried out using the R version 2.14.2 software16 and the Biocon-
ductor packages,17 as described recently.18,19 Following background
correction, expression data were normalized with the variance sta-
bilization and normalization algorithm,20 and log2 transformed using
the median polish algorithm of robust multiarray average.21 The qual-
ity of the data was assessed with the affy22 and the arrayQualityMetrics23
packages. We ensured adequate quality of the entire resulting data set
using standard quality metrics and graphical tools, confirming that there
were no outliers and that diseased and control tissues could be com-
pared. To detect differences in transcript cluster expression between
conditions, a moderated linear model was applied using the limma
package.24 To adjust resulting P-values, the false discovery rate (FDR)
was controlled. Pathway analysis was performed by means of gene set
enrichment analysis25,26 querying the Kyoto Encyclopedia of Genes and
Genomes (KEGG) database27 and by using the Category and GSEABase
packages. The distribution was computed based on 1000 permutations
adjusting for multiple testing. Statistical significance was considered at
FDR-adjusted P≤ 0.05 at all times.
Quantitative real-time RT–PCR
Reverse transcription and quantitative real-time PCR were performed
as described previously.28,29 Total RNA was reverse transcribed and
amplified using the One Step RT qPCR MasterMix (Eurogentec) in a
LS480 Lightcycler (Roche). Reactions where RNA or reverse transcrip-
tase had been omitted were used as negative controls. PCR products
were obtained using gene-specific, intron-spanning primers. The lev-
els of all candidate genes were normalized to ribosomal protein L32
(RPL32) housekeeping mRNA levels. Primer sequences used for ampli-
fication and product sizes are shown in Supplementary material online
Table S6.
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Histology
The LV tissue samples were fixed in 4% formaldehyde, embedded in
paraffin, cut into 3 μm sections and stained with chromotrope aniline
blue (CAB) using standard procedures.
Immunoblotting
The LV samples were homogenized in a modified RIPA buffer (50mM
Tris–HCl, pH 7.4, 150mM NaCl, 1mM EDTA, 1% NP-40, 0.25%
Na-deoxycholate) supplemented with protease inhibitor cocktail
(Roche), and the phosphatase inhibitors sodium orthovanadate (1mM
Na3VO4) and sodium fluoride (1mM NaF). Proteins were quan-
tified using the BCA Assay (Pierce), resolved by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS–PAGE), transferred
to nitrocellulose membranes, and incubated with antibodies against
CD3 (Thermo Scientific) and tubulin (Sigma). Immunoreactive proteins
were detected using ECL Plus (GE Healthcare).
Statistical analysis
All data were analysed statistically using the SPSS version 21 and R
version 2.14.2 software. Multivariate normality of the data was tested
using the E-statistic.30 Comparisons between two groups were per-
formed with unpaired t-test or Mann–Whitney U-test, and between
multiple groups using two-way analysis of variance with Tukey’s
post-hoc test adjusting for multiple comparisons. Categorical variables
were tested using 𝜒2 test. A P-value ≤0.05 was considered statistically
significant.
Factor analysis was used to analyse LV remodelling under conditions
of chronic PO.31,32 Following ASE guidelines, LV end-diastolic diam-
eter (LVEDD) was used as a marker for dilation, and LV mass and
relative wall thickness (RWT) as markers for concentricity. Mean and
peak transvalvular pressure gradients were also included. Themeasures .
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.. related to LV remodelling were combined in the LV remodelling index
and forced orthogonal to the PO index (combines mean and peak
transvalvular pressure gradients). The Kaiser–Meyer–Olkin (KMO)
measure of sampling adequacy was 0.374, while the Bartlett’s test of
sphericity was highly significant (P< 0.0001). Principal component anal-
ysis with Varimax rotation was used as the underlying factor-analytical
method. The Kaiser–Guttman criterion was applied to ascertain the
number of extracted factors. We used the LV remodelling index to
classify echocardiographic LV remodelling into adaptive or maladaptive
patterns. Since the LV remodelling index is a z-transformed variable,
positive index values correlate with an increase in LVEDD (factor load-
ing 0.962) and LV mass (factor loading 0.661) and a decrease in RWT
(factor loading –0.818), thereby reflecting maladaptive LV remodelling.
The LV remodelling pattern was considered adaptive when the crite-
ria for maladaptive LV remodelling were not fulfilled, i.e. negative LV
remodelling index values.
Results
Patient characteristics and sex-specific
left ventricular remodelling
The study population was composed of 48 men and 56 women
(Table 1). The prevalence of diabetes mellitus, hyperlipidaemia,
hypertension, and CAD was similar between men and women.
Women compared with men had significantly smaller LV end-
diastolic diameter and LV mass, and greater RWT. LVEF and
transvalvular pressure gradients were similar between the sexes.
Our analysis of LV remodelling patterns revealed a statistically
significant difference between men and women. In particular, mal-
adaptive remodelling was present in 64.6% of men, while it was
present in 32.7% of women (Figure 1).
Table 1 Baseline characteristics of the study population
Total (n= 104) Men (n= 48) Women (n= 56) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years 70± 9.4 69± 10 70± 9 0.836
Body mass index, kg/m2 28± 4.5 28± 3.6 28± 5.2 0.758
Systolic blood pressure, mmHg 136±18 137±19 136±17 0.657
Diastolic blood pressure, mmHg 72±11 74± 8 70± 13 0.052
Diabetes mellitus, % 29 33 25 0.350
Hyperlipidaemia, % 57 52 61 0.376
Hypertension, % 88 88 88 1.000
Coronary artery disease, % 5 8 2 0.179
LVEDD, mm 48± 6 50± 5 46± 6 0.001
Left ventricular mass, g 233± 59 250± 56 217± 58 0.004
Relative wall thickness 0.5± 0.08 0.48± 0.07 0.52± 0.09 0.036
Mean pressure gradient, mmHg 58±12 57± 11 58± 13 0.654
Maximal pressure gradient, mmHg 83±19 85± 16 81± 21 0.290
Left ventricular ejection fraction, % 62± 4 61± 4 62± 5 0.189
ACE inhibitors, % 45 45 45 0.997
Beta-blockers, % 50 47 54 0.494
Diuretics, % 40 43 38 0.602
Values are shown as mean± SD or %.
LVEDD, left ventricular end-diastolic diameter
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Figure 1 Proportion of male and female patients with mal-
adaptive LV remodelling. The LV remodelling index (see the
Methods) revealed that a significantly greater number of male
patients (n= 48) had maladaptive remodelling than female patients
(n= 56). **P< 0.01.
Transcriptome analysis reveals
sex-specific regulation of fibrotic
and inflammatory genes/pathways
in human left ventricular remodelling
Following genome-wide expression profiling of intraoperative
myocardial biopsies in a representative subgroup of 19 patients
(52.6% women; maladaptive LV remodelling: 60% men, 40%
women), we obtained valid data on 32 321 transcript clusters.
Applying an FDR-adjusted P-value threshold of 0.05, we identified
2873 transcript clusters regulated in male tissues, while 3491
transcript clusters were regulated in female tissues (Figure 2A).
Of these, 1382 transcript clusters were significantly regulated in
both sexes, while the remaining clusters were specific for each sex
(Figure 2A). This demonstrates that although there is a substantial
overlap in gene regulation, there are significant differences in the
genomic response to PO between men and women.
Within the genes regulated in both male and female tissues,
several known markers associated with PO and LV hypertrophy
can be found (Supplementary material online, Table S1), includ-
ing the myosin light chain 4 (MYL4), natriuretic peptide A (NPPA),
and myocyte enhancer factor 2A (MEF2A) genes. However, exam-
ining the behaviour of the commonly regulated genes, we discov-
ered that the extent of the regulation of a number of these genes
differed considerably between the sexes (Figure 2B and C). Con-
sidering genes whose behaviour was most different between men
and women, we found that among others, extracellular membrane
(ECM)- and fibrosis-related genes were induced to a higher degree
in male PO tissues than in female PO tissues compared with con-
trols (Figure 2D), while inflammation-related genes were repressed
to a higher degree in female PO tissues than in male PO tissues
compared with controls (Figure 2E).
Functional enrichment analysis using Gene Ontology terms
revealed that in male tissues the expression of genes belonging to
fibrotic processes, such as collagen fibril organization, transforming
growth factor-beta (TGF-𝛽) receptor, and the bone morphogenic ..
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.. protein (BMP) signalling pathway, was increased. On the other
hand, in female tissues, the expression of inflammatory genes
involved in regulation of B cell-mediated immunity and regulation of
alpha–beta T-cell activation was repressed.
Employing the KEGG database, we found that the ECM–
receptor interaction, peroxisome proliferator-activated recep-
tor (PPAR), p53, TGF-𝛽, and Fc𝜀RI signalling pathways were
induced in male PO tissues only (adjusted P< 0.05; Table 2
and Supplementary material online, Table S4). On the other
hand, we found that a large number of inflammatory pathways,
such as the cytokine–cytokine receptor interaction, cell adhe-
sion molecules, natural killer cell-mediated cytotoxicity, phago-
some, Toll-like receptor, and Jak–STAT signalling pathways, were
repressed in female PO hearts (adjusted P< 0.05; Table 2 and Sup-
plementary material online, Table S5).
Confirmation of increased fibrosis
and inflammation in male hearts
Due to the prominent sex differences in ECM/fibrosis-related
and inflammatory genes/pathways identified by our whole-
transcriptome analysis, we selected candidates within these bio-
logical processes for the validation of the resulting high-throughput
data. Quantitative real-time RT–PCR confirmed that although the
expression of the ECM gene asporin (ASPN)33 was significantly
increased in both male and female PO tissues compared with
controls, this increase was significantly higher in male than in
female tissues (Figure 3A). Furthermore, as in the genome-wide
expression profiling, the expression of TIMP metallopeptidase
inhibitor 2 (TIMP2), chemokine (C-X3-C motif) receptor 1
(CX3CR1), interleukin 33 (IL33), and Toll-like receptor 7 (TLR7)
was increased in male tissues only, and the expression of TGF-𝛽1
(TGFB1) was decreased in female tissues only (Figure 3A). In
line with these gene expression patterns, male tissues displayed
much more increased fibrous, pericellular collagen depositions
than female tissues as illustrated by the CAB staining (Figure 3B).
Moreover, immunoblotting analysis demonstrated that the protein
levels of proinflammatory CD3 were higher in male than in female
tissues (Figure 3C). Taken together, these data demonstrate the
validity of our findings by confirming the selected candidates from
the whole-transcriptome analysis through different experimental
approaches.
Discussion
Differences in the development, progression, and outcome of
PO-induced LV hypertrophy between men and women have been
well documented and have long been expected to arise from
different molecular mechanisms active between the sexes. Our
work is the first to show how the molecular response to PO differs
between men and women and that the male heart increases fibrosis
and inflammatory pathways, while the female heart suppresses
fibrosis-related and inflammatory processes.
Initially, we performed differential expression analysis at the sin-
gle gene level comparing the LV transcriptome of male and female
© 2014 The Authors
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Figure 2 Comparison of differential gene expression. (A) Venn diagram showing the number of transcript clusters regulated in cardiac tissues
of male and of female patients and those regulated in common compared with controls. (B) and (C) Volcano plots of significance of genes against
their relative change in expression. Circles represent all transcript clusters present in the data set. For each transcript cluster, the negative log10
of the P-value is plotted against the relative change in gene expression. The dashed horizontal line indicates the significance threshold (P< 0.05)
after false discovery rate correction for multiple testing. Transcripts regulated in male tissues only are shown in blue (B), those regulated in
female tissues only are in red (C), and those that were regulated in common are shown in green for both sexes. (D) and (E) Expression plots
for extracellular matrix (ECM)-, fibrosis-, and inflammation-related genes. In pressure overload, ECM- and fibrosis-related genes were induced
more in male tissues than in female tissues (D), while inflammation-related genes were more repressed in female tissues than in male tissues (E)
compared with controls. Data are shown as fold change related to control. n= 8–10/group. ASPN, asporin; LTBP2, latent transforming growth
factor beta binding protein 2; MATN2, matrilin 2; OMD, osteomodulin; AQP3, aquaporin 3; DLK1, delta-like 1 homologue; LILRB3, leucocyte
immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 3; SECTM1, secreted and transmembrane 1.
patients with the LV transcriptome of men and women with no car-
diovascular disease. As anticipated, several genes were regulated in
both male and female tissues. For instance, the expression of NPPA
andMEF2Awas increased in response to PO. This was expected, as
both genes have a prominent role in LV remodelling, demonstrating
the validity of our approach.34,35 However, we found a number of
genes commonly regulated in male and female tissues that had a
different extent of regulation between the sexes. This was the case
with ECM- and fibrosis-related genes, which had higher expression
in male than in female aortic stenosis tissues. The stronger induc-
tion of these genes in male tissues supports the view that a higher
degree of fibrosis occurring in the hearts of male patients with .
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.. aortic stenosis may play a key role in the worse outcome observed
in men.
Fibrogenesis is a necessary process that follows stress and injury,
such as myocardial infarction and hypertrophy. Consequently, initial
activation of fibrotic factors is crucial for the heart to maintain its
integrity and function. However, persistent fibrosis and excessive
ECM remodelling contribute to disease progression and may lead
to heart failure. The hallmark of fibrosis is the differentiation of
fibroblasts to myofibroblasts, which in turn mediate tissue remod-
elling. Myofibroblasts can be activated by TGF-𝛽, angiotensin II, and
other cytokines. To this extent, we found that the ECM–receptor
© 2014 The Authors
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Table 2 Top 10 Kyoto Encyclopedia of Genes and Genomes pathways regulated in male or female diseased vs. control
left ventricular tissues
ID Name Adjusted P-value Regulation
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Male
04512 Extracellular matrix–receptor interaction <0.001 Up
04614 Renin–angiotensin system <0.001 Up
04622 RIG-I-like receptor signalling pathway <0.001 Up
04350 Transforming growth factor-beta signalling pathway 0.005 Up
04510 Focal adhesion 0.005 Up
04310 Wnt signalling pathway 0.006 Up
03010 Ribosome <0.001 Down
04260 Cardiac muscle contraction 0.002 Down
03050 Proteasome 0.004 Down
00190 Oxidative phosphorylation 0.005 Down
Female
03430 Mismatch repair 0.006 Up
04146 Peroxisome 0.011 Up
04060 Cytokine–cytokine receptor interaction <0.001 Down
04062 Chemokine signalling pathway <0.001 Down
04514 Cell adhesion molecules (CAMs) <0.001 Down
04610 Complement and coagulation cascades <0.001 Down
04620 Toll-like receptor signalling pathway <0.001 Down
04630 Jak–STAT signalling pathway < 0.001 Down
04650 Natural killer cell-mediated cytotoxicity < 0.001 Down
04145 Phagosome 0.001 Down
interaction, renin–angiotensin system, and TGF-𝛽 signalling path-
ways were activated only in male patients. Furthermore, our anal-
ysis at the single gene level demonstrated that the gene with
the highest fold increase in male PO tissues compared with con-
trols was periostin (POSTN). Periostin is an ECM protein activated
when fibroblasts convert to myofibroblasts and is a mediator of
fibrosis.36,37 Cardiac-specific overexpression of periostin increases
LV collagen deposition, while its deletion decreases LV hypertro-
phy and fibrosis.37 In addition, the expression of many more ECM
proteins, such as collagen type I and III, was increased in the hearts
of men with aortic stenosis. The broad activation of profibrotic
molecular mediators therefore denotes that excessive fibrosis and
ECM remodelling occur in male hearts, contributing to severe LV
dilation and cardiac dysfunction.
In contrast, female hypertrophied hearts showed an active sup-
pression of profibrotic factors. In particular, the gene encoding
TGF-𝛽 itself (TGFB1) was repressed, as well as that of angiotensino-
gen (AGT), the precursor of angiotensin II. Moreover, we observed
a co-ordinated and generalized repression of chemokine- and
cytokine-related and inflammatory pathways. These could be key
mechanisms against the progression of fibrosis, as it has been
shown that fibroblast progenitor cells, known as fibrocytes, are
recruited to the heart and mediate fibrosis.38 Cardiomyocytes may
produce cytokines, promoting a profibrotic environment. Further-
more, chemokines and their receptors are crucial for fibrocyte
and leucocyte migration. Therefore, in addition to the evident pro-
tection against the detrimental effects of increased inflammation .
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. through the inhibition of proinflammatory factors, the present find-
ings suggest that female PO-stressed hearts may be further pro-
tected against uncontrolled fibrosis, preventing fibrocyte migration
through the reduced expression of cell adhesive molecules. The
overall validation of ECM/fibrosis-related and inflammatory mark-
ers through different experimental approaches underscores the
robustness of these findings.
Limitations
Our transcriptome analysis was constrained by a relatively small
sample size stratified by sex, related to limited heart material
available from closely matched living individuals. However, the
internal consistency and validation of our findings by different
experimental approaches support the conclusions demonstrating
differences in the cardiac gene signature between men and women
in PO. A further limitation is the deviation between the KMO
measure of sampling adequacy and the Bartlett’s test of sphericity.
While the KMO measure was not satisfactory, the Bartlett’s
test indicated strong relationships among the assessed variables
appropriate for factor analysis.
Conclusions
In conclusion, the present study demonstrates how the response of
the cardiac transcriptome to PO differs between men and women.
In view of the pronounced sex-specific regulation of fibrotic
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Figure 3 Validation of genome-wide expression profiling. (A)
Relative mRNA levels of selected candidates were quantified
by qRT–PCR in LV samples from male and female patients and
normalized to ribosomal protein L32 (RPL32). Since there were
no sex differences at basal expression, data are shown as fold
change related to control. n= 9–10/group; *P< 0.05, **P< 0.01,
and ***P< 0.001 for diseased vs. control; §P< 0.05 and §§P< 0.01
for male diseased vs. female diseased. ASPN, asporin; TIMP2,
TIMP metallopeptidase inhibitor 2; CX3CR1, chemokine (C-X3-C
motif) receptor 1; IL33, interleukin 33; TLR7, Toll-like receptor
7; TGFB1, transforming growth factor-beta 1. (B) Representative
chromotrope aniline blue (CAB)-stained LV sections showing
collagen deposition (light blue) in two male and two female
patients. Scale bar= 100 μm. (C) Representative western blotting
analysis of LV homogenates from three male and two female
patients. Levels of CD3 protein were determined using a specific
antibody. Tubulin served as loading control.
and inflammatory markers, we anticipate that these are major
underlying mechanisms responsible for the differences observed
in the clinical outcome of PO-induced stress between men and
women, thereby influencing the progression to heart failure. We
put forward that sex-specific therapeutic interventions may be of
increased value towards a more personalized medical care. Fur-
thermore, the integration of biomarkers for both fibrosis and
inflammation might be a clinical tool useful for early identification
of changes in these pathways. ..
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